|
|
|
|
REFERENCES
Brinton LA: The relationship of exogenous estrogens to cancer risk. Cancer Detect Prevent 7:159-171, 1984. Brinton LA: Estrogen replacement therapy and endometrial cancer: Unresolved issues. Obstet Gynecol 81:265-271, 1993. Brinton LA and Schairer C: Estrogen replacement therapy and breast cancer risk. Epidemiologic Reviews 15:66-79, 1993. Burch JC, Byrd BF and Vaughn WK: The effects of long-term estrogen administration to women following hysterectomy. Front Horm Res 3:208-214, 1975. Davis FG, Furner SE, Persky V, et al.: The influence of parity and exogenous female hormones on the risk of colorectal cancer. Int J Cancer 43:587-590, 1989. Furner SE, Davis FG, Nelson RL, et al.: A case-control study of large bowel cancer and hormone exposure in women. Cancer Res 49:4936-4940, 1989. Gallagher RP, Elwood JM, Rootman J, et al.: Risk factors for ocular melanoma: Western Canada melanoma study.
J Natl Cancer Inst 74:775-778, 1985. Hartge P, Tucker MA, Shields JA, et al.: Case-control study
of female hormones and eye melanoma. Cancer Res 49:4622-4625, 1989. International Agency for Research on Cancer: Overall Evaluations of Carcinogenicity: An Updating of IARC Monographs vols 1 to 42. [Suppl 7], 1987. Kelsey JL and Gammon MD: Epidemiology of breast cancer. Epidemiol Rev 12:228-240, 1990. Milne R and Vessey M: The association of oral contraception with kidney cancer, colon cancer, gallbladder cancer (including extrahepatic bile duct cancer) and pituitary tumors. Contraception 43:667-693, 1991. Persson I, Adami HO, Bergkvist L, et al.: The risk of endometrial cancer after treatment with oestrogens
alone or in conjunction with progestogens: results of a prospective study. BMJ 298(6667):147-151, 1989. Potter JD and McMichael AJ: Large bowel cancer in women in relation to reproductive and hormonal factors: A case-control study. J Natl Cancer Inst 71:703-709, 1983. Rosenberg L: The risk of liver neoplasia in relation to
combined oral contraceptive use. Contraception
43:643-652, 1991. Skegg DCG, Noonan EA, Paul C, et al.: Depot-
medroxyprogesterone acetate and breast cancer: a pooled analysis of the World Health Organization and New Zealand studies. JAMA 273:799-804, 1994. Stanford JL, Brinton LA, Berman ML, et al.: Oral contraceptives and endometrial cancer risk: Do other risk factors modify the association? Intl J Cancer 54:243-248, 1993. Thomas DB: Steroid hormones and medications that alter cancer risks. Cancer 62:1755-1767, 1988. Van Leeuwen FE and Rookus MA: The role of exogenous
hormones in the epidemiology of breast, ovarian
and endometrial cancer. Eur J Cancer Clin Oncol
25:1961-1972, 1989. Vessey MP: Epidemiologic studies of the effects of
diethylstilboestrol. In Perinatal and Multigeneration Carcinogenesis, IARC Scientific Publication No. 96,
pp 335-348, 1989. Vessey M and Grice D: Carcinoma of the cervix and oral contraceptives: epidemiological studies. Biomed Pharmacother 43:157-160, 1989. Weiss NS and Daling JR and Chow WH: Incidence of
cancer of the large bowel in relation to reproductive and hormonal factors. J Natl Cancer Inst 67:57-60, 1981. World Health Organization. Depot-medroxyprogesterone acetate (DMPA) and cancer: Memorandum from a WHO meeting. Bull World Health Organ 64:375-382, 1986. World Health Organization. Combined oral contraceptives and liver cancer. Int J Cancer 43:254-259, 1989. World Health Organization. Depot-medroxyprogesterone acetate (DMPA) and risk of liver cancer. Int J Cancer 49:182-185, 1991. |
